Thermo Fisher, AstraZeneca team on CDx test for Tagrisso

As part of a global, multiyear agreement, Thermo Fisher Scientific (TMO) announced it is working with AstraZeneca (AZN) to develop a solid tissue and blood-based companion diagnostic CDx test for Tagrisso or osimertinib . The CDx will help identify patients with non-small cell lung cancer NSCLC who may be eligible for treatment with Tagrisso by identifying tumors that exhibit epidermal growth factor receptor ,EGFR,alterations including exon 21 L858R mutations, exon 19 deletions or T790M mutations. The collaboration will leverage the Oncomine Dx Express Test on the Genexus Dx System , a fully-integrated next-generation sequencing platform featuring an automated specimen-to-report workflow that economically delivers results in as little as 24 hours to bring test results to clinicians and patients faster. NGS-based CDx testing offers the ability to detect multiple biomarkers from a single test, helping to match patients with an appropriate targeted therapy more quickly. The need for faster diagnostic turnaround times was reinforced by research presented at ASCO 2022 that found patients with advanced stage NSCLC had better outcomes, including survival rates, when molecular testing results were available early enough to inform initial treatment decisions.